Overview
Background
Dr Mollee practices as a consultant haematologist in clinical and laboratory haematology at the Princess Alexandra Hospital and is Associate Professor with the University of Queensland Medical School.
Having trained in Brisbane and Toronto, Dr Mollee has developed an international reputation studying amyloidosis and the plasma cell dyscrasias. He holds appointments with the Medical Scientific Advisory Group of Myeloma Australia, Australian Amyloidosis Network, National Blood Cancer Taskforce and is a member of the AACB Monoclonal Gammopathy Working Group and the International Kidney & Monoclonal Gammopathy Research Group. He is a past Chairman of the Australasian Leukaemia and Lymphoma Group (ALLG) and current Chair of the Australian Amyloidosis Network. He heads the Myeloma Service as well as the Queensland Amyloidosis Centre which runs one of the few clinics in Australia dedicated exclusively to the care of patients with amyloidosis.
Availability
- Associate Professor Peter Mollee is:
- Available for supervision
Qualifications
- Masters (Coursework) of Medical Science, University of Newcastle
- Royal Australasian College of Physicians, Royal Australasian College of Physicians
- Royal College of Pathologists of Australasia, Royal College of Pathologists of Australasia
Research impacts
The research of the Queensland Amyloidosis Centre aims to improved the diagnosis, monitoring and therapy of all types of amyloidosis. The Centre, in collaboration with Pathology Queensland and the Translational Research Institute, developed laser capture macrodisscution and tandem mass spectrometry analysis to accurately diagnosis the type of amyloidosis that patients have and have introuduced this assay into the clinical laboratory. Research to improve the diagnosis and monitoring of this rare disease has also assessed immunoglobulin free light chain assays, bone scintigraphy and novel radionuclide PET tracers. The Queensland Amyloidosis Centre maintains an active clinical trial program in amyloidosis therapies including both investigator-initiated and commercial studies.
Works
Search Professor Peter Mollee’s works on UQ eSpace
2021
Journal Article
Imaging of patients with multiple myeloma and associated plasma cell disorders: consensus practice statement by the Medical Scientific Advisory Group to Myeloma Australia
Creeper, Katherine, Augustson, Bradley, Kusel, Kieran, Fulham, Michael J., Ho, Joy, Quach, Hang, Mollee, Peter, Weber, Nicholas, Talaulikar, Dipti, Johnston, Anna, Murphy, Nick, Joshua, Douglas, Ward, Christopher, Ling, Silvia, Gibson, John, Szer, Jeff, Harrison, Simon, Zannettino, Andrew, Jaksic, Wilfrid, Lee, Cindy, Spencer, Andrew, Kalff, Anna, Szabo, Ferenc, Romeril, Ken, Chan, Henry, Gibbs, Simon, Horvath, Noemi and Prince, H. Miles (2021). Imaging of patients with multiple myeloma and associated plasma cell disorders: consensus practice statement by the Medical Scientific Advisory Group to Myeloma Australia. Internal Medicine Journal, 51 (10), 1707-1712. doi: 10.1111/imj.15457
2021
Journal Article
Daratumumab-based treatment for immunoglobulin light-chain amyloidosis
Kastritis, E., Palladini, G., Minnema, M. C., Wechalekar, A. D., Jaccard, A., Lee, H. C., Sanchorawala,, Gibbs, S., Mollee, P., Venner, C. P., Lu, J., Schonland, S., Gatt, M. E., Suzuki, K., Kim, K., Cibeira, M. T., Beksac, M., Libby, E., Valent, J., Hungria,, Wong, S. W., Rosenzweig, M., Bumma, N., Huart, A., Dimopoulos, M. A., Bhutani, D., Waxman, A. J., Goodman, S. A., Zonder, J. A. ... Comenzo, R. L. (2021). Daratumumab-based treatment for immunoglobulin light-chain amyloidosis. The New England Journal of Medicine, 385 (1), 46-58. doi: 10.1056/NEJMoa2028631
2021
Journal Article
Daratumumab-based treatment for immunoglobulin light-chain amyloidosis
Kastritis, Efstathios, Palladini, Giovanni, Minnema, Monique C., Wechalekar, Ashutosh D., Jaccard, Arnaud, Lee, Hans C., Sanchorawala, Vaishali, Gibbs, Simon, Mollee, Peter, Venner, Christopher P., Lu, Jin, Schönland, Stefan, Gatt, Moshe E., Suzuki, Kenshi, Kim, Kihyun, Cibeira, M. Teresa, Beksac, Meral, Libby, Edward, Valent, Jason, Hungria, Vania, Wong, Sandy W., Rosenzweig, Michael, Bumma, Naresh, Huart, Antoine, Dimopoulos, Meletios A., Bhutani, Divaya, Waxman, Adam J., Goodman, Stacey A., Zonder, Jeffrey A. ... Comenzo, Raymond L. (2021). Daratumumab-based treatment for immunoglobulin light-chain amyloidosis. New England Journal of Medicine, 385 (1), 46-58. doi: 10.1056/NEJMoa2028631
2021
Journal Article
Receiving four or fewer cycles of therapy predicts poor survival in newly diagnosed transplant-ineligible patients with myeloma who are treated with bortezomib-based induction
Boyle, Stephen, Wellard, Cameron, Moore, Elizabeth M., Blacklock, Hilary, Harrison, Simon J., Ho, Phoebe Joy, Hocking, Jay, McQuilten, Zoe K., Quach, Hang, Spearing, Ruth, Wood, Erica M., Spencer, Andrew and Mollee, Peter (2021). Receiving four or fewer cycles of therapy predicts poor survival in newly diagnosed transplant-ineligible patients with myeloma who are treated with bortezomib-based induction. European Journal of Haematology, 107 (4) ejh.13677, 497-499. doi: 10.1111/ejh.13677
2021
Journal Article
The myeloma landscape in Australia and New Zealand: the first 8 years of the Myeloma and Related Diseases Registry (MRDR)
Bergin, Krystal, Wellard, Cameron, Moore, Elizabeth, McQuilten, Zoe, Blacklock, Hilary, Harrison, Simon J., Ho, P. Joy, King, Tracy, Quach, Hang, Mollee, Peter, Walker, Patricia, Wood, Erica and Spencer, Andrew (2021). The myeloma landscape in Australia and New Zealand: the first 8 years of the Myeloma and Related Diseases Registry (MRDR). Clinical Lymphoma, Myeloma and Leukemia, 21 (6), e510-e520. doi: 10.1016/j.clml.2021.01.016
2021
Journal Article
Real-world utilisation of ASCT in multiple myeloma (MM): a report from the Australian and New Zealand myeloma and related diseases registry (MRDR)
Bergin, Krystal, Wellard, Cameron, Augustson, Bradley, Cooke, Rachel, Blacklock, Hilary, Harrison, Simon J., Ho, Joy, King, Tracy, Quach, Hang, Mollee, Peter, Walker, Patricia, Moore, Elizabeth, McQuilten, Zoe, Wood, Erica, Spencer, Andrew and on behalf of the Australian and New Zealand Myeloma and Related Diseases Registry (2021). Real-world utilisation of ASCT in multiple myeloma (MM): a report from the Australian and New Zealand myeloma and related diseases registry (MRDR). Bone Marrow Transplantation, 56 (10), 2533-2543. doi: 10.1038/s41409-021-01308-8
2021
Journal Article
The Clinical Impact of Proteomics in Amyloid Typing
Hill, Michelle M., Dasari, Surendra, Mollee, Peter, Merlini, Giampaolo, Costello, Catherine E., Hazenberg, Bouke P.C., Grogan, Martha, Dispenzieri, Angela, Gertz, Morie A., Kourelis, Taxiarchis and McPhail, Ellen D. (2021). The Clinical Impact of Proteomics in Amyloid Typing. Mayo Clinic Proceedings, 96 (5), 1122-1127. doi: 10.1016/j.mayocp.2020.12.002
2021
Journal Article
Response of factor X deficiency to darutumumab in the treatment of AL amyloidosis: a novel finding
Mar, Ethan, Taylor, Kerry and Mollee, Peter (2021). Response of factor X deficiency to darutumumab in the treatment of AL amyloidosis: a novel finding. BMJ Case Reports, 14 (4) e240631, 4. doi: 10.1136/bcr-2020-240631
2021
Journal Article
Peripherally Inserted Central catheter iNnovation to reduce Infections and Clots (the PICNIC trial): a randomised controlled trial protocol
Ullman, Amanda J., August, Deanne, Kleidon, Tricia, Walker, Rachel, Marsh, Nicole M., Bulmer, Andrew, Pearch, Benjamin, Runnegar, Naomi, Schults, Jessica A., Leema, Joanne, Lee-Archer, Paul, Biles, Cathy, Southam, Katrina, Gibson, Victoria, Byrnes, Joshua, Ware, Robert S., Chopra, Vineet, Coulthard, Alan, Mollee, Peter, Rickard, Claire M. and Harris, Patrick N. A. (2021). Peripherally Inserted Central catheter iNnovation to reduce Infections and Clots (the PICNIC trial): a randomised controlled trial protocol. BMJ Open, 11 (4) e042475, 1-7. doi: 10.1136/bmjopen-2020-042475
2021
Other Outputs
A cost-effectiveness analysis of front-line treatment strategies in early stage follicular lymphoma
Tobin, Joshua W.D., Crothers, Anna, Eric, Ti, Mollee, Peter, Gandhi, Maher K., Scuffham, Paul and Hapgood, Greg (2021). A cost-effectiveness analysis of front-line treatment strategies in early stage follicular lymphoma. doi: 10.1101/2021.03.24.21254220
2021
Journal Article
Correction: HDAC7 is an actionable driver of therapeutic antibody resistance by macrophages from CLL patients (Oncogene, (2020), 39, 35, (5756-5767), 10.1038/s41388-020-01394-w)
Burgess, M., Chen, Y. C.E., Mapp, S., Blumenthal, A., Mollee, P., Gill, D. and Saunders, N. A. (2021). Correction: HDAC7 is an actionable driver of therapeutic antibody resistance by macrophages from CLL patients (Oncogene, (2020), 39, 35, (5756-5767), 10.1038/s41388-020-01394-w). Oncogene, 40 (6), 1203-1203. doi: 10.1038/s41388-020-01619-y
2021
Journal Article
SIRPα suppresses response to therapeutic antibodies by nurse like cells from chronic lymphocytic leukemia patients
Chen, Yu-Chen Enya, Burgess, Melinda, Mapp, Sally, Mollee, Peter, Gill, Devinder, Blumenthal, Antje and Saunders, Nicholas A. (2021). SIRPα suppresses response to therapeutic antibodies by nurse like cells from chronic lymphocytic leukemia patients. Frontiers in Immunology, 11 610523, 1-12. doi: 10.3389/fimmu.2020.610523
2021
Journal Article
Health-related quality of life in transplant-ineligible patients with newly diagnosed multiple myeloma: Findings from the phase III MAIA trial
Perrot, Aurore, Facon, Thierry, Plesner, Torben, Usmani, Saad Z., Kumar, Shaji, Bahlis, Nizar J., Hulin, Cyrille, Orlowski, Robert Z., Nahi, Hareth, Mollee, Peter, Ramasamy, Karthik, Roussel, Murielle, Jaccard, Arnaud, Delforge, Michel, Karlin, Lionel, Arnulf, Bertrand, Chari, Ajai, He, Jianming, Ho, Kai Fai, van Rampelbergh, Rian, Uhlar, Clarissa M., Wang, Jianping, Kobos, Rachel, Gries, Katharine S., Fastenau, John and Weisel, Katja (2021). Health-related quality of life in transplant-ineligible patients with newly diagnosed multiple myeloma: Findings from the phase III MAIA trial. Journal of Clinical Oncology, 39 (3), 227-237. doi: 10.1200/JCO.20.01370
2021
Journal Article
The association of mobilising regimen on immune reconstitution and survival in myeloma patients treated with bortezomib, cyclophosphamide and dexamethasone induction followed by a melphalan autograft
Rees, Matthew J., Mollee, Peter, Ng, Jun Yen, Murton, Alex, Gonsalves, Jose Filipe, Panigrahi, Ashish, Beer, Hayley, Loh, Joanna, Nguyen, Philip, Hunt, Sam, Jina, Hayden, Wayte, Rebecca, Sutrave, Gaurav, Tan, Jocelyn, Abeyakoon, Chathuri, Chee, Ashlyn, Augustson, Bradley, Kalro, Akash, Lee, Cindy, Agrawal, Shivam, Churilov, Leonid, Chua, Chong Chyn, Lim, Andrew Boon Ming, Zantomio, Daniela and Grigg, Andrew (2021). The association of mobilising regimen on immune reconstitution and survival in myeloma patients treated with bortezomib, cyclophosphamide and dexamethasone induction followed by a melphalan autograft. Bone Marrow Transplantation, 56 (9), 2152-2159. doi: 10.1038/s41409-021-01300-2
2021
Journal Article
A cost-effectiveness analysis of front-line treatment strategies in early-stage follicular lymphoma
Tobin, Joshua W. D., Crothers, Anna, Ma, Ti Eric, Mollee, Peter, Gandhi, Maher K., Scuffham, Paul and Hapgood, Greg (2021). A cost-effectiveness analysis of front-line treatment strategies in early-stage follicular lymphoma. Leukemia and Lymphoma, 62 (14), 1-9. doi: 10.1080/10428194.2021.1957866
2021
Journal Article
Report of the Survey Conducted by RCPAQAP on Current Practices for Beta-Migrating Paraprotein Reporting
Smith, Joel D, Wijeratne, Nilika, Schneider, Hans G, de Malmanche, Theo, Hissaria, Pravin, Toit, Stephen Du, Chiu, Weldon, Boyder, Conchita, Morison, Ian M, Tseng, Anfernee, Glegg, Kaye, Wienholt, Louise, Mollee, Peter and on behalf of the AACB/RCPA Monoclonal Gammopathy Working Party (2021). Report of the Survey Conducted by RCPAQAP on Current Practices for Beta-Migrating Paraprotein Reporting. Clinical Biochemist Reviews, 42 (1), 11-16. doi: 10.33176/AACB-21-00001
2021
Journal Article
The use of monocyte subset repartitioning by flow cytometry for diagnosis of chronic myelomonocytic leukaemia
Murali, Aarya, Cross, Donna and Mollee, Peter (2021). The use of monocyte subset repartitioning by flow cytometry for diagnosis of chronic myelomonocytic leukaemia. Blood Cancer Journal, 11 (1) 6, 6. doi: 10.1038/s41408-020-00401-3
2020
Journal Article
Catheter-related thrombosis incidence and risk factors in adult cancer patients with central venous access devices
Ellis, Marc L., Okano, Satomi, McCann, Andrew, McDowall, Angela, Van Kuilenburg, Rosita, McCarthy, Alexandra L., Joubert, Warren, Harper, John, Jones, Mark and Mollee, Peter (2020). Catheter-related thrombosis incidence and risk factors in adult cancer patients with central venous access devices. Internal Medicine Journal, 50 (12), 1475-1482. doi: 10.1111/imj.14780
2020
Journal Article
A Randomized Study of Bortezomib, Cyclophosphamide and Dexamethasone Induction (VCD) Versus VCD and Daratumumab Induction Followed By Daratumumab Maintenance (VCDD) for the Initial Treatment of Transplant-Ineligible Patients with Multiple Myeloma (AMaRC 03-16)
Mollee, Peter, Reynolds, John, Janowski, Wojt, Quach, Hang, Campbell, Philip, Gibbs, Simon D., Lee, Sophie, D'Rozario, James, Taylor, Kerry, Cochrane, Tara, Wallington-Beddoe, Craig Thomas, Kwok, Fiona, Weber, Nicholas, Kerridge, Ian H., Weston, Helen, Ho, Phoebe Joy, Horvath, Noemi, Yuen, Flora and Spencer, Andrew (2020). A Randomized Study of Bortezomib, Cyclophosphamide and Dexamethasone Induction (VCD) Versus VCD and Daratumumab Induction Followed By Daratumumab Maintenance (VCDD) for the Initial Treatment of Transplant-Ineligible Patients with Multiple Myeloma (AMaRC 03-16). Blood, 136 (Supplement 1), 4-5. doi: 10.1182/blood-2020-138394
2020
Conference Publication
A cost-effectiveness analysis of front-line treatment strategies in early stage follicular lymphoma
Tobin, Joshua W.D., Hapgood, Greg, Gandhi, Maher K., Mollee, Peter, Ma, Ti, Crothers, Anna and Scuffham, Paul (2020). A cost-effectiveness analysis of front-line treatment strategies in early stage follicular lymphoma. 62nd ASH Annual Meeting and Exposition, Online, 5-8 December 2020. Washington, DC USA: American Society of Hematology. doi: 10.1182/blood-2020-138590
Supervision
Availability
- Associate Professor Peter Mollee is:
- Available for supervision
Before you email them, read our advice on how to contact a supervisor.
Supervision history
Current supervision
-
Master Philosophy
Novel Radionuclide Tracers for Imaging in Amyloidosis
Principal Advisor
Other advisors: Associate Professor Colm Keane
-
Doctor Philosophy
Addressing frailty in older people with haematological malignancies
Associate Advisor
Other advisors: Associate Professor Emily Gordon, Dr Natasha Reid, Professor Ruth Hubbard
Media
Enquiries
For media enquiries about Associate Professor Peter Mollee's areas of expertise, story ideas and help finding experts, contact our Media team: